Abstract 1385P
Background
Selective RET inhibitors transformed the treatment (tx) paradigm of RET fusion-positive (RET+) lung cancers. For selpercatinib, the median progression free survival (PFS) is 22.0 months (mos) for tx naive patients and 24.9 mos for platinum doublet pretreated patients. Genomic factors associated with early versus late progression are unknown.
Methods
We analyzed data from 80 patients with RET+ LC identified between January 2014 and March 2023 utilizing a DNA-based hybrid capture tumor next generation tumor sequencing assay (MSK-IMPACT) and plasma ctDNA assay (MSK-ACCESS). Patients with radiologic progression (PD) on selpercatinib ≤ 3 mos from initiation were classified as “rapid progressors”, >3- 24 mos as “intermediate progressors”, and ≥24 months as“late progressors.” Baseline and post-PD MSK-IMPACT and MSK-ACCESS specimens were evaluated. Patients with post-PD biopsies were evaluated for acquired resistance (AR) (classified as on-target (secondary RET mutations), off-target (non-RET OncoKB level 1-4), and unknown).
Results
Among 80 patients with RET+ LC, 63 had pre-tx tumor sequencing and 35 patients had post-tx tumor/ctDNA sequencing. 58% (n=46/80) progressed on selpercatinib. PD was classified as rapid, intermediate, and late in 9% (n=7), 35% (n=28), 14% (n=11), respectively. Acquired resistance (AR) was identified in 48% of cases. Six patients had on-target AR and 17 patients had off-target AR. Most common off-target AR included MET amp (9%), KRAS mutation (6%), PIK3CA mutation (6%), CDKN2A mutation (6%), and FGFR1 amp (6%). There were no differences in age, gender, ethnicity, prior tx, or PDL1 status between these groups. Pre-tx TP53, KEAP1, and ARID1A mutations were more common in rapid and intermediate versus late PD (p=0.03, p=0.02, p=0.06). Off-target mechanisms of resistance appeared to be enriched in rapid and early progressors vs late progressors (75% vs 51% vs 25%, p=0.3).
Conclusions
RET fusion+ NSCLCs that progressed on selpercatinib prior to two years, an approximation of the drug’s median PFS, were enriched for select co-occurring alterations (e.g., TP53, KEAP1, and ARID1A mutations) in pre-tx samples and off-target resistance in post-PD samples.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
R01 CA251591.
Disclosure
E. Rosen: Financial Interests, Personal, Research Funding: Bayer. S.R. Yang: Financial Interests, Personal, Other, Honoraria: Prime Education; Financial Interests, Personal, Advisory Role: InVitae. M.G. Kris: Financial Interests, Personal, Research Grant: Boehringer Ingelheim, National Lung Cancer Partnership, Pfizer, Puma, Stand up to cancer; Financial Interests, Personal, Speaker, Consultant, Advisor: Ariad, AstraZeneca, Bind Biosciences, Boehringer Ingelheim, Chugai Pharma, Clovis, Covidien, Daiichi Sankyo, Genentech, Novartis, Millenium, Pfizer, Roche. A. Drilon: Financial Interests, Personal, Advisory Board: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millennium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, BeiGene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem Oncology, More Health, AbbVie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX, Amgen, Janssen, EcoR1, Monte Rosa; Financial Interests, Personal, Other, CME: Medscape, Onclive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, PeerView Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Medscape, Clinical Care Options, AiCME; Financial Interests, Personal, Other, CME, Consulting: Axis; Financial Interests, Personal, Other, Consulting: Nuvalent, Merus, EPG Health, mBrace, Harborside Nexus, Ology, TouchIME, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc; Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical, Remedica Ltd, RV More; Financial Interests, Personal, Stocks/Shares: Treeline Biosciences; Financial Interests, Personal, Royalties: Wolters Kluwer; Financial Interests, Personal, Other, stocks: mBrace; Financial Interests, Institutional, Funding, Research funding: Pfizer, Exelixis, PharmaMar, GSK, Teva, Taiho; Financial Interests, Personal, Funding, Research: Foundation Medicine; Non-Financial Interests, Member: ASCO, AACR, IASLC; Other, Food/Beverage: Merck, PUMA, Merus; Other: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20